Escolar Documentos
Profissional Documentos
Cultura Documentos
Roberto Cosimo Melcangi, PhD,* Donatella Caruso, PhD,* Federico Abbiati, PhD Student,*
Silvia Giatti, PhD,* Donato Calabrese, PhD Student,* Fabrizio Piazza, PhD, and Guido Cavaletti, MD
*Department of Pharmacological and Biomolecular SciencesCenter of Excellence on Neurodegenerative Diseases,
University of Milan, Milano, Italy; Department of Surgery and Translational Medicine, University of Milan-Bicocca,
Monza, Italy; Department of Neurology, S. Gerardo Hospital, Monza, Italy
DOI: 10.1111/jsm.12269
ABSTRACT
Introduction. Observations performed in a subset of subjects treated with nasteride (an inhibitor of the enzyme
5a-reductase) for male pattern hair loss seem to indicate that sexual dysfunction as well as anxious/depressive
symptomatology may occur at the end of the treatment and continue after discontinuation.
Aim. A possible hypothesis to explain depression symptoms after nasteride treatment might be impairment in
the levels of neuroactive steroids. Therefore, neuroactive steroid levels were evaluated in paired plasma and
cerebrospinal uid samples obtained from male patients who received nasteride for the treatment of androgenic
alopecia and who, after drug discontinuation, still show long-term sexual side effects as well as anxious/depressive
symptomatology.
Methods. The levels of neuroactive steroids were evaluated by liquid chromatographytandem mass spectrometry in
three postnasteride patients and compared to those of ve healthy controls.
Main Outcome Measures. Neuroactive steroid levels in plasma and cerebrospinal uid of postnasteride patients
and healthy controls.
Results. At the examination, the three postnasteride patients reported muscular stiffness, cramps, tremors, and
chronic fatigue in the absence of clinical evidence of any muscular disorder or strength reduction. Severity and
frequency of the anxious/depressive symptoms were quite variable; overall, all the subjects had a fairly complex
and constant neuropsychiatric pattern. Assessment of neuroactive steroid levels in patients showed some interindi-
vidual differences. However, the most important nding was the comparison of their neuroactive steroid levels with
those of healthy controls. Indeed, decreased levels of tetrahydroprogesterone, isopregnanolone and dihydrotest-
osterone and increased levels of testosterone and 17b-estradiol were reported in cerebrospinal uid of postnasteride
patients. Moreover, decreased levels of dihydroprogesterone and increased levels of 5a-androstane-3a,17b-diol and
17b-estradiol were observed in plasma.
Conclusion. The present observations conrm that an impairment of neuroactive steroid levels, associated with
depression symptoms, is still present in androgenic alopecia patients treated with nasteride despite the discontinu-
ation of the treatment. Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, and Cavaletti G.
Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of postfinasteride patients showing
persistent sexual side effects and anxious/depressive symptomatology. J Sex Med 2013;10:25982603.
Key Words. Progesterone; Testosterone; 5a-Reductase; Depression; Liquid ChromatographyTandem Mass
Spectrometry
Table 1 General data and self-reported frequency of the most severe symptoms reported by the patients at the moment of cerebrospinal fluid sampling
Patient 1 Patient 2 Patient 3
Table 2 Levels of neuroactive steroids in cerebrospinal fluid of post-finasteride patients and controls
PREG PROG DHP THP Isopregnanolone DHEA T DHT 3a-diol 3b-diol 17a-E 17b-E
Patients
1 1.16 0.30 u.d.l. u.d.l. u.d.l. 0.24 0.07 0.29 0.26 u.d.l. 0.03 0.06
2 1.10 0.36 u.d.l. u.d.l. u.d.l. 0.38 0.25 0.35 0.29 u.d.l. u.d.l. 0.06
3 0.23 0.11 u.d.l. u.d.l. u.d.l. 0.13 0.14 0.18 0.13 u.d.l. u.d.l. u.d.l.
Mean 0.83 0.26 u.d.l. u.d.l. u.d.l. 0.25 0.15 0.27 0.23 u.d.l. 0.023 0.047
SEM 0.3 0.07 0.07 0.052 0.05 0.05 0.003 0.013
Students t-test ** * * * *
Controls
1 0.74 0.15 u.d.l. 0.32 1.11 0.12 0.07 0.49 0.23 u.d.l. u.d.l. u.d.l.
2 0.95 0.16 u.d.l. 0.34 0.38 0.18 0.08 0.27 0.44 u.d.l. u.d.l. u.d.l.
3 0.91 0.10 u.d.l. 0.77 0.44 0.14 0.05 0.80 0.44 u.d.l. u.d.l. u.d.l.
4 0.71 0.19 u.d.l. 0.51 0.15 0.16 0.09 1.26 0.38 u.d.l. u.d.l. u.d.l.
5 0.70 0.18 u.d.l. 0.45 0.49 0.16 0.09 1.00 0.23 u.d.l. u.d.l. u.d.l.
Mean 0.80 0.16 u.d.l. 0.48 0.51 0.15 0.08 0.76 0.34 u.d.l. u.d.l. u.d.l.
SEM 0.05 0.002 0.08 0.16 0.01 0.007 0.18 0.05
muscular disorder or strength reduction. To (Table 3). In this patient the CSF levels of 17b-E
perform a complete neurological assessment, were also under detection limit, in contrast to
before CSF drawing (4 mL) under sterile condi- those of patients 1 and 2 (Table 2).
tions after local anesthesia, the postnasteride Levels of DHEA in all patients were quite
patients underwent brain magnetic resonance similar in CSF (Table 2), but not in plasma, where
imaging, with normal results in all subjects. The they were much higher in patient 2 in comparison
standard examination of CSF (i.e., protein, with the others (Table 3). A quite similar pattern
glucose, and cellular content) was normal in all was present for T (Tables 2 and 3). Thus, CSF
cases. levels were comparable, but patient 3 showed
The levels of pregnenolone (PREG), PROG higher plasma levels in comparison to patient 1
and its derivatives, DHP, THP and isopreg- and 2 (Table 2).
nanolone, dehydroepiandrosterone (DHEA), test- In comparison with the healthy controls, the
osterone (T) and its derivatives, DHT, 3a-diol, three patients presented a quite different neuroac-
3b-diol, 17a-estradiol (17a-E), and 17b- tive steroid pattern. In particular, as reported in
estradiol (17b-E) were evaluated by liquid Table 2, CSF levels of THP and isopregnanolone
chromatographytandem mass spectrometry (LC- were under detection limit in all three patients. By
MS/MS) in plasma and CSF as previously applying Students t-test, it was found that the
described [18,19]. The levels of neuroactive ste- CSF levels of THP and isopregnanolone in post-
roids in CSF and plasma of the three postnas- nasteride patients were signicantly different
teride patients were compared with those of ve from those of the healthy controls (THP, P < 0.01;
male, age-matched controls, represented by sub- isopregnanolone, P = 0.05). THP levels were also
jects who underwent a diagnostic lumbar puncture under detection limit in the plasma (Table 3).
for a suspected neurological disease but eventually Moreover, as reported in Table 3, plasma levels
proved to be healthy; the CSF and plasma were of DHP (the precursor of THP and isopreg-
obtained at the S. Gerardo Hospital CSF and nanolone) were under detection limit in all three
plasma bank (Tables 2 and 3). patients and signicantly different compared with
As reported, neuroactive steroid levels were those of healthy controls (P < 0.001). As reported
very similar in patients 1 and 2, and they were in Table 2, T and DHT levels were, respectively,
slightly different from those observed in patient 3. higher and lower in the CSF of patients as com-
In particular, patient 3 showed lower PREG and pared with controls (P < 0.05). CSF levels of
PROG levels in both CSF (Table 2) and plasma 17b-E were also signicantly higher in postnas-
(Table 3), higher isopregnanolone levels in plasma teride patients than in healthy controls (P < 0.05).
(Table 3), and levels of DHT, 3a-diol, 3b-diol, and As reported in Table 3, plasma levels of DHT and
17b-E that were under detection limit in plasma of its metabolites (3a-diol and 3b-diol) were under
detection limit only in patient 3. Plasma levels of depressive symptomatology occurring despite dis-
3a-diol and 17b-E (Table 3) in the three postn- continuation of nasteride treatment in male
asteride patients were signicantly higher than in patients with pattern hair loss and indicate the
the healthy controls (P < 0.05). need for a conrmatory study in a larger cohort of
The present results show for the rst time, in patients.
three male patients with pattern hair loss, that
persistent sexual side effects and anxious/
depressive symptomatology despite discontinua- Acknowledgments
tion of nasteride are associated with changes in
The authors thank the study subjects for their time and
CSF and plasma levels of neuroactive steroids. In participation. We also thank the Post-Finasteride Foun-
particular, in CSF we observed a decrease in dation and the nancial support of Fondazione San
metabolites of PROG and T, such as THP, iso- Paolo (Progetto Neuroscienze PF-2009.1180) to R.C.
pregnanolone, and DHT, associated with an Melcangi.
increase in T and 17b-E. In contrast, in plasma, a
decrease in DHP levels associated with an increase Corresponding Author: Roberto Cosimo Mel-
of 3a-diol and 17b-E was observed. The few cangi, PhD, Department of Pharmacological and Bio-
observations so far present in the literature have molecular SciencesSection of Biomedicine and
EndocrinologyCenter of Excellence in Neurodegen-
mainly focused on the role of 3a-reduced metabo-
erative Diseases, University of Milan, Italy, Via Balza-
lites of PROG and particularly of THP in anxious/ retti 9, 20133 Milano, Italy. Tel: +39-02-50318238; Fax:
depressive symptomatology. Indeed, there is +39-02-50318204; E-mail: roberto.melcangi@unimi.it
general agreement that THP is decreased in CSF
and plasma in patients with anxious/depressive Conict of Interest: The authors report no conicts of
symptomatology and that this disequilibrium can interest.
be corrected with different antidepressants [17,20
22]. Interestingly, we here observed a decrease not
only in THP but also in isopregnanolone in CSF, Statement of Authorship
as well as a decrease in levels of THPs precursor Category 1
DHP in plasma. Moreover, we also report a (a) Conception and Design
decrease in DHT in CSF. Indeed, association Roberto Cosimo Melcangi; Guido Cavaletti
between androgen deciency and depression has (b) Acquisition of Data
also been proposed [23]. Altogether, these results Guido Cavaletti; Federico Abbiati; Donato Cala-
provide a molecular basis for the anxious/ brese; Silvia Giatti; Fabrizio Piazza
(c) Analysis and Interpretation of Data 10 Altomare G, Capella GL. Depression circumstantially related
Roberto Cosimo Melcangi; Donatella Caruso; to the administration of nasteride for androgenetic alopecia.
J Dermatol 2002;29:6659.
Guido Cavaletti
11 Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki
A. Finasteride induced depression: A prospective study. BMC
Category 2 Clin Pharmacol 2006;6:7.
(a) Drafting the Article 12 Irwig MS. Depressive symptoms and suicidal thoughts among
Roberto Cosimo Melcangi; Donatella Caruso; former users of nasteride with persistent sexual side effects.
J Clin Psychiatry 2012;73:12203.
Guido Cavaletti
13 Schumacher M, Hussain R, Gago N, Oudinet JP, Mattern C,
(b) Revising It for Intellectual Content Ghoumari AM. Progesterone synthesis in the nervous system:
Roberto Cosimo Melcangi; Donatella Caruso; Implications for myelination and myelin repair. Front Neuro-
Guido Cavaletti sci 2012;6:10. doi: 10.3389/fnins.2012.00010
14 Panzica GC, Balthazart J, Frye CA, Garcia-Segura LM, Her-
Category 3 bison AE, Mensah-Nyagan AG, McCarthy MM, Melcangi
RC. Milestones on Steroids and the Nervous System: 10 years
(a) Final Approval of the Completed Article of basic and translational research. J Neuroendocrinol
Roberto Cosimo Melcangi; Donatella Caruso; 2012;24:115.
Guido Cavaletti 15 Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3
a-hydroxy-5 a[b]-pregnan-20-one: Endogenous metabolites
of progesterone that are active at the GABAA receptor. Brain
Res 1991;561:15761.
References 16 Wang M, He Y, Eisenman LN, Fields C, Zeng CM, Mathews
J, Benz A, Fu T, Zorumski E, Steinbach JH, Covey DF,
1 Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gilil- Zorumski CF, Mennerick S. 3b-hydroxypregnane steroids
land KR, Gorin-Meyer RE, Wiren KM. A new look at the are pregnenolone sulfate-like GABA(A) receptor antagonists.
5a-reductase inhibitor nasteride. CNS Drug Rev 2006;12: J Neurosci 2002;22:336675.
5376. 17 Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S.
2 Traish AM. 5a-reductases in human physiology: An unfolding Neurosteroids, stress and depression: Potential therapeutic
story. Endocr Pract 2012;18:96575. opportunities. Neurosci Biobehav Rev 2013;37:10922.
3 Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG. 18 Caruso D, Pesaresi M, Maschi O, Giatti S, Garcia-Segura LM,
Neuroactive steroids: State of the art and new perspectives. Melcangi RC. Effects of short- and long-term gonadectomy on
Cell Mol Life Sci 2008;65:77797. neuroactive steroid levels in the central and peripheral nervous
4 Handa RJ, Pak TR, Kudwa AE, Lund TD, Hinds L. An system of male and female rats. J Neuroendocrinol 2010;22:
alternate pathway for androgen regulation of brain function: 113747.
Activation of estrogen receptor beta by the metabolite of dihy- 19 Caruso D, Barron AM, Brown MA, Abbiati F, Carrero P, Pike
drotestosterone, 5a-androstane-3b,17b-diol. Horm Behav CJ, Garcia-Segura LM, Melcangi RC. Age-related changes in
2008;53:74152. neuroactive steroid levels in 3Tg-AD mice. Neurobiol Aging
5 Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, 2013;34:10809.
Ellis ML, Wilson T, Rittmaster RS. The importance of dual 20 Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B,
5a-reductase inhibition in the treatment of male pattern hair Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant
loss: Results of a randomized placebo-controlled study of treatment on neuroactive steroids in major depression. Am J
dutasteride versus nasteride. J Am Acad Dermatol 2006;55: Psychiatry 1998;155:9103.
101423. 21 Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP,
6 McClellan KJ, Markham A. Finasteride: A review of its use in Costa E, Guidotti A. Increase in the cerebrospinal uid
male pattern hair loss. Drugs 1999;57:11126. content of neurosteroids in patients with unipolar major
7 Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, depression who are receiving uoxetine or uvoxamine. Proc
Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky Natl Acad Sci U S A 1998;95:323944.
M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the 22 Uzunova V, Sampson L, Uzunov DP. Relevance of
treatment of men with androgenetic alopecia. Finasteride endogenous 3a-reduced neurosteroids to depression and anti-
Male Pattern Hair Loss Study Group. J Am Acad Dermatol depressant action. Psychopharmacology (Berl) 2006;186:351
1998;39:57889. 61.
8 Irwig MS. Persistent sexual side effects of nasteride: Could 23 Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML.
they be permanent? J Sex Med 2012;9:292732. Adverse side effects of 5a-reductase inhibitors therapy: Persis-
9 Irwig MS, Kolukula S. Persistent sexual side effects of nas- tent diminished libido and erectile dysfunction and depression
teride for male pattern hair loss. J Sex Med 2011;8:174753. in a subset of patients. J Sex Med 2011;8:87284.